Vanguard Group Inc. Has $107.34 Million Stock Position in NeoGenomics, Inc. $NEO

Key Points

• Vanguard trimmed its stake in NeoGenomics by 1.6% in Q3, leaving it with 13,903,735 shares — about a 10.75% ownership position valued at roughly $107.34 million.
• COO Warren Stone sold 22,128 shares (≈$276,600) on Jan. 20, cutting his holdings by 15.39% to 121,631 shares; company insiders now own about 2.4% of the stock while institutional ownership is ~98.5%.
• NeoGenomics slightly beat Q4 estimates (EPS $0.06 vs $0.04, revenue $190.2M vs $188.3M) but remains unprofitable (negative P/E and net margin); the stock trades near $9.10 with a market cap of ~$1.18B and a consensus analyst rating of Hold (target $11.86).

Vanguard Group Inc. lessened its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 1.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,903,735 shares of the medical research company's stock after selling 227,026 shares during the quarter. Vanguard Group Inc. owned 10.75% of NeoGenomics worth $107,337,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Squarepoint Ops LLC grew its stake in shares of NeoGenomics by 246.8% in the 2nd quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company's stock worth $5,376,000 after acquiring an additional 523,407 shares in the last quarter. Aberdeen Group plc increased its position in NeoGenomics by 91.8% in the third quarter. Aberdeen Group plc now owns 792,263 shares of the medical research company's stock worth $6,116,000 after buying an additional 379,165 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in NeoGenomics during the third quarter valued at about $1,281,000. Geode Capital Management LLC grew its stake in NeoGenomics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 3,156,621 shares of the medical research company's stock valued at $23,078,000 after buying an additional 26,224 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. bought a new position in NeoGenomics in the 2nd quarter worth about $292,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Warren Stone sold 22,128 shares of NeoGenomics stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the sale, the chief operating officer owned 121,631 shares of the company's stock, valued at $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.40% of the stock is currently owned by company insiders.

NeoGenomics Trading Down 4.6%

Shares of NASDAQ NEO opened at $9.10 on Thursday. NeoGenomics, Inc. has a 1 year low of $4.72 and a 1 year high of $13.74. The firm has a 50-day moving average of $11.69 and a 200 day moving average of $10.38. The stock has a market cap of $1.18 billion, a P/E ratio of -10.83 and a beta of 1.62. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.26 and a quick ratio of 3.94.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The firm had revenue of $190.17 million for the quarter, compared to analysts' expectations of $188.25 million. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.04 earnings per share. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on NEO shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NeoGenomics in a report on Monday, December 29th. UBS Group reiterated a "hold" rating on shares of NeoGenomics in a report on Wednesday, February 18th. Zacks Research lowered NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 20th. TD Cowen reiterated a "buy" rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Finally, Benchmark restated a "hold" rating on shares of NeoGenomics in a research report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, NeoGenomics presently has a consensus rating of "Hold" and a consensus target price of $11.86.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company's core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.